2023 / 05

DOI: 10.24075/brsmu.2023.043

ORIGINAL RESEARCH

Features of CD163+ and HLA-DR+ expression on blood monocytes associated with breast cancer

Patysheva MR1,2, Stakheyeva MN1,2, Grigoryeva ES2, Tarabanovskaya NA1, Bragina OD1, Kzhyshkowska JG2,3, Cherdyntseva NV1,2
About authors

1 Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia

2 National Research Tomsk State University, Tomsk, Russia

3 University of Heidelberg, Mannheim, Germany

Correspondence should be addressed: Marina R. Patysheva
per. Kooperativnyi, 7/1, Tomsk, 634009, Russia; ur.cmint.ocno@rm_avehsytap

About paper

Funding: the study was supported by the RSF grant (№ 22-25-00435).

Acknowledgments: we would like to express our gratitude to О.Е. Savelieva, the lead researcher at the Institute of Personalized Psychiatry and Neurology, Bekhterev National Research Medical Center for Psychiatry and Neurology (Saint Petersburg), for assistance in conducting flow cytometry.

Author contribution: Patysheva MR — study design, flow cytometry, data analysis, manuscript writing; Stakheyeva MN — study concept, study design, data analysis, manuscript writing; Grigoryeva ES — flow cytometry; Tarabanovskaya NA — selection of patients, patient clinical data acquisition; Bragina OD — selection of patients, patient clinical data acquisition; Kzhyshkowska JG — study concept, search for funding, discussion; Cherdyntseva NV — study design, discussion.

Compliance with ethical standards: the study was approved by the Ethics Committee of the Cancer Research Institute, Tomsk National Research Medical Center (protocol № 10 dated 05 December 2019). All subjects submitted the informed consent to study participation.

Received: 2023-09-14 Accepted: 2023-10-10 Published online: 2023-10-31
|
  1. Ziegler-Heitbrock L. Blood monocytes and their subsets: established features and open questions. Frontiers in immunology. 2015; 6: 423.
  2. Xin Fu MY. Monocytes in tumor: The perspectives of single-cell analysis. Tumor Discovery. 2022; 1 (1): 4.
  3. Mildner A, Schönheit J, Giladi A, David E, Lara-Astiaso D, Lorenzo-Vivas E, et al. Genomic Characterization of Murine Monocytes Reveals C/EBPβ Transcription Factor Dependence of Ly6C(-) Cells. Immunity. 2017; 46 (5): 849–62.e7.
  4. Kapellos TS, Bonaguro L, Gemünd I, Reusch N, Saglam A, Hinkley ER, et al. Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Frontiers in immunology. 2019; 10: 2035.
  5. Skytthe MK, Graversen JH, Moestrup SK. Targeting of CD163(+) Macrophages in Inflammatory and Malignant Diseases. International journal of molecular sciences. 2020; 21 (15).
  6. Joshi I, Carney WP, Rock EP. Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis. Frontiers in immunology. 2023; 14: 1130214.
  7. Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nature immunology. 2018; 19 (2): 108–19.
  8. Wang YA, Jian JW, Hung CF, Peng HP, Yang CF, Cheng HS, et al. Germline breast cancer susceptibility gene mutations and breast cancer outcomes. BMC cancer. 2018; 18 (1): 315.
  9. Olsson HL, Olsson ML. The menstrual cycle and risk of breast cancer: a review. Frontiers in oncology. 2020; 10: 21.
  10. Brown KA. Metabolic pathways in obesity-related breast cancer. Nature reviews Endocrinology. 2021; 17 (6): 350–63.
  11. Byun D, Hong S, Ryu S, Nam Y, Jang H, Cho Y, et al. Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose-response meta-analysis of prospective studies. British journal of cancer. 2022; 126 (4): 664–72.
  12. Liu K, Zhang W, Dai Z, Wang M, Tian T, Liu X, et al. Association between body mass index and breast cancer risk: evidence based on a dose-response meta-analysis. Cancer management and research. 2018; 10: 143–51.
  13. Koh J, Kim MJ. Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage. Korean journal of radiology. 2019; 20 (1): 69–82.
  14. Urru SAM, Gallus S, Bosetti C, Moi T, Medda R, Sollai E, et al. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. BMC cancer. 2018; 18 (1): 56.
  15. Morris RM, Mortimer TO, O'Neill KL. Cytokines: can cancer get the message? Cancers. 2022; 14 (9).
  16. Niraula A, Sheridan JF. IL6 signaling in monocytes: a potential therapeutic avenue for stress-induced mood impairments. Chronic stress (Thousand Oaks, Calif). 2019; 3.
  17. Hanna RN, Cekic C, Sag D, Tacke R, Thomas GD, Nowyhed H, et al. Patrolling monocytes control tumor metastasis to the lung. Science (New York, NY). 2015; 350 (6263): 985–90.
  18. Lee J, Tam H, Adler L, Ilstad-Minnihan A, Macaubas C, Mellins ED. The MHC class II antigen presentation pathway in human monocytes differs by subset and is regulated by cytokines. PloS one. 2017; 12 (8): e0183594.
  19. Patysheva M, Larionova I, Stakheyeva M, Grigoryeva E, Iamshchikov P, Tarabanovskaya N, et al. Effect of early-stage human breast carcinoma on monocyte programming. Frontiers in oncology. 2021; 11: 800235.
  20. Stenmark Tullberg A, Sjöström M, Niméus E, Killander F, Chang SL, Feng FY, et al. Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023; 29 (9): 1783–93.
  21. Loizides S, Constantinidou A. Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy. Frontiers in genetics. 2022; 13: 1095839.
  22. Kartikasari AER, Huertas CS, Mitchell A, Plebanski M. TumorInduced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis. Frontiers in oncology. 2021; 11: 692142.
  23. Knüpfer H, Preiss R. Significance of interleukin-6 (IL6) in breast cancer. Breast cancer research and treatment. 2007; 102 (2): 129–35.
  24. Chen J, Wei Y, Yang W, Huang Q, Chen Y, Zeng K, et al. IL6: the link between inflammation, immunity and breast cancer. Frontiers in oncology. 2022; 12: 903800.
  25. Chen J, Wei Y, Yang W, Huang Q, Chen Y, Zeng K, et al. IL6: the link between inflammation, immunity and breast cancer. Frontiers in oncology. 2022; 12: 903800.